Lineage Cell Therapeutics, Inc. (LCTX) vs Lyell Immunopharma, Inc. (LYEL)
Lineage Cell Therapeutics, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Lyell Immunopharma, Inc. are of similar size ($248.0M and $239.7M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −55.0%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −920,285.2%) and the higher return on invested capital (−186.8% vs −539.5%). Across the 18 metrics below, Lineage Cell Therapeutics, Inc. leads on 13 and Lyell Immunopharma, Inc. on 5.
Valuation
Profitability
| Metric | LCTX | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.46% | 100.00% | 65.16% |
| Operating margin | (205.23%) | (949,981.48%) | 0.00% |
| Net margin | (246.58%) | (920,285.19%) | 0.00% |
| Free cash flow margin | (186.43%) | (647,681.48%) | 0.00% |
| Return on equity | (60.35%) | (93.28%) | (57.72%) |
| Return on assets | (32.75%) | (71.34%) | (49.22%) |
| Return on invested capital | (186.79%) | (539.53%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack